Salivary Inflammatory Biomarkers: Predictors & Comparative Effects of Sonicare/Elite-Flexcare in Stages of Perio Disease

NCT ID: NCT02187185

Last Updated: 2018-08-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

175 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-04-30

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research study has 2 aims. One aim is to see if saliva testing can show if a person has healthy gum tissue, gingivitis, or one of three degrees of periodontitis - mild, moderate, or severe. The second aim is to examine the effect of the Sonicare Elite/Flexcare toothbrush on periodontitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Randomized controlled trial to determine clinical and inflammatory benefits of Sonicare Flexcare tooth brushing following experimental induction of biofilm overgrowth in various periodontal conditions.

This research study has both a Diagnostic Aim and a Treatment Aim. Aim #1 is to examine the utility of candidate inflammatory biomarkers within saliva to discriminate between health, gingivitis, mild, moderate and severe periodontis; and to discriminate between active versus inactive states of periodontal disease to see if these basal levels can predict the clinical response to biofilm overgrowth among various periodontal conditions; Aim #2 is to extend the claim of the anti-inflammatory and anti-infective efficacy of the Sonicare/Elite-Flexcare as compared to manual brushing to include 4 levels of periodontal disease \[BGI-G, P1, P2 and P3\].

The devices used in this study are subject only to Class I (general controls) and considered exempt from the premarket notification procedures and not subject to section 510(k), 515, or 520(m,) of the FDC Act in order to be legally marketed. Thus, the study does not meet the definition of an Applicable Clinical Trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammation Periodontitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sonicare Elite-Flexcare

Arm 1 participants will abstain from brushing and flossing teeth in selected sites which will typically be one maxillary and mandibular posterior sextant during a three week, no-hygiene phase via placement of acrylic stents. After the stent-induced biofilm overgrowth (SIBO) induction, the resolution phase of the study will involve a randomization that places half of the subjects on the Sonicare/Elite/Flexcare toothbrush. Thus, the resolution phase is a RCT designed to treat SIBO in subjects with varying levels of disease. Participants will reinstate normal full mouth oral hygiene and daily plaque control, exclusive of flossing, with dispensed dentifrice and toothbrush. Participants will be followed for four weeks during SIBO resolution.

Group Type ACTIVE_COMPARATOR

Sonicare/Elite-Flexcare Toothbrush

Intervention Type OTHER

Philips Oral Healthcare product - battery powered menchanic toothbrush with nylon bristles

Manual Toothbrush

Arm 2 participants will abstain from brushing and flossing teeth in selected sites which will typically be one maxillary and mandibular posterior sextant during a three week, no-hygiene phase via placement of acrylic stents. After the stent-induced biofilm overgrowth (SIBO) induction, the resolution phase of the study will involve a randomization that places half of the subjects on the manual toothbrush. Thus, the resolution phase is a RCT designed to treat SIBO in subjects with varying levels of disease. Participants will reinstate normal full mouth oral hygiene and daily plaque control, exclusive of flossing, with dispensed dentifrice and toothbrush. Participants will be followed for four weeks during SIBO resolution.

Group Type ACTIVE_COMPARATOR

Manual Toothbrush

Intervention Type OTHER

traditional (non-mechanical) toothbrush with nylon bristles and plastic handle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sonicare/Elite-Flexcare Toothbrush

Philips Oral Healthcare product - battery powered menchanic toothbrush with nylon bristles

Intervention Type OTHER

Manual Toothbrush

traditional (non-mechanical) toothbrush with nylon bristles and plastic handle

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. adult males or females between the ages of 18 and 75 years (inclusive).
2. able and willing to follow study procedures and instructions.
3. read, understood and signed an informed consent form.
4. present with at least 8 teeth in the functional dentition with a minimum of 3 adjacent teeth with interproximal papilla in each posterior sextant that will have the stent.
5. be in good general health.
6. present with one of the following five categories to be considered for enrollment

* BGI health (all PD\<3mm, BOP\<10%)
* BGI-gingivitis (all PD≤3mm, BOP≥10%)
* BGI-P1 (1+ site with PD\>3mm, BOP≤10%)
* BGI-P2 (1+ site with PD\>3mm, BOP\>10% but BOP≤50%)
* BGI-P3 (1+ site with PD\>3mm, BOP\>50%)

Exclusion Criteria

1. chronic disease with oral manifestations or active infectious diseases such as hepatitis, HIV or tuberculosis.
2. gross oral pathology.
3. treatment with antibiotics for any medical or dental condition within 1 month prior to the screening examination.
4. chronic treatment (i.e., two weeks or more) with any medication known to affect periodontal status (e.g., phenytoin, calcium antagonists, cyclosporin, anticoagulants, non-steroidal anti-inflammatory drugs, high dose aspirin such as \>100mg per day) within one month of the screening examination.
5. ongoing medications initiated less than three months prior to enrollment (i.e., medications for chronic medical conditions must be initiated at least three months prior to enrollment).
6. clinically significant organ disease including impaired renal function, and/or any bleeding disorder.
7. severe unrestored caries, or any condition that is likely to require antibiotic treatment during the study, including the need for prophylactic antibiotic.
8. use any tobacco products or who have used tobacco products within the previous six months of the screening examination.
9. pregnant, or expect to become pregnant within the next three months and individuals nursing.
10. dental appliances that will interfere with stent construction.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Philips Oral Healthcare

INDUSTRY

Sponsor Role collaborator

University of North Carolina, Chapel Hill

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Steven Offenbacher, DDS PhD MMSc

Role: PRINCIPAL_INVESTIGATOR

The University of North Carolina at Chapel Hill School of Dentistry

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The University of North Carolina at Chapel Hill School of Dentistry

Chapel Hill, North Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

09-0627

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Philips AirFlosser Study
NCT01700348 TERMINATED NA
Assessing Gingivitis and Plaque From a Marketed Toothpaste
NCT07158112 ACTIVE_NOT_RECRUITING PHASE4
Stannous Fluoride and Gingivitis
NCT05326373 COMPLETED NA